Navidea biopharmaceuticals reports third quarter and year-to-date 2020 financial results

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended september 30, 2020. “navidea continues to build on its clinical momentum and this quarter fully shows our ability to execute during a very trying time globally,” said mr. jed a. latkin, c
NAVB Ratings Summary
NAVB Quant Ranking